Baudax Bio to Present at the H.C. Wainwright BioConnect 2021 Conference

Rhea-AI Summary

Baudax Bio (NASDAQ:BXRX) announces that its President and CEO, Gerri Henwood, will present a corporate overview at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 a.m. ET on Baudax's website, remaining accessible for 30 days post-event. Baudax Bio, focused on therapeutics for acute care, launched its first product, ANJESO, in June 2020 after FDA approval. ANJESO is a once-daily IV NSAID for managing moderate to severe pain.

MALVERN, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021.

The presentation will be available for on-demand listening beginning Monday, January 11^th at 6:00 a.m. Eastern Time and may be accessed on the “Presentations” page within the Investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be available for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO^® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential COX-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information please visit www.baudaxbio.com.

CONTACT:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
sam@argotpartners.com
claudia@argotpartners.com

Baudax Bio, Inc.
Ryan D. Lake
(484) 395-2436
rlake@baudaxbio.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com

FAQ

When will Gerri Henwood present at the H.C. Wainwright BioConnect 2021 Conference for BXRX?

Gerri Henwood will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021.

Where can I access the presentation by Baudax Bio at the BioConnect conference?

The presentation will be available on Baudax Bio's website under the 'Presentations' section starting January 11, 2021.

What is ANJESO and when was it launched by Baudax Bio?

ANJESO is a once-daily IV NSAID launched by Baudax Bio in June 2020, approved by the FDA in February 2020.

What is the significance of the H.C. Wainwright BioConnect 2021 Conference for BXRX?

The conference provides a platform for Baudax Bio to present a corporate overview, highlighting its developments and products to investors.

How long will the presentation from Baudax Bio be available for viewing?

The presentation will be accessible for 30 days following the event, starting January 11, 2021.